Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) Director Wendy B. Young bought 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was bought at an average price of $10.21 per share, with a total value of $61,260.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at $61,260. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Rapport Therapeutics Trading Up 4.9 %
NASDAQ:RAPP opened at $10.51 on Friday. Rapport Therapeutics has a twelve month low of $6.43 and a twelve month high of $29.74. The company has a 50-day moving average of $13.54 and a 200-day moving average of $18.73. The firm has a market cap of $383.57 million and a price-to-earnings ratio of -0.76.
Hedge Funds Weigh In On Rapport Therapeutics
Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new position in shares of Rapport Therapeutics during the 3rd quarter valued at about $34,000. KLP Kapitalforvaltning AS purchased a new stake in Rapport Therapeutics during the fourth quarter valued at about $34,000. Deutsche Bank AG purchased a new stake in Rapport Therapeutics during the fourth quarter valued at about $41,000. New York State Common Retirement Fund purchased a new stake in shares of Rapport Therapeutics in the fourth quarter worth approximately $62,000. Finally, Virtus ETF Advisers LLC purchased a new stake in shares of Rapport Therapeutics in the fourth quarter worth approximately $66,000.
About Rapport Therapeutics
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
- Five stocks we like better than Rapport Therapeutics
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is a Secondary Public Offering? What Investors Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.